Skip to main content
NCBI home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1985 Feb;84(2):551–560. doi: 10.1111/j.1476-5381.1985.tb12940.x

Platelet release reaction and aggregation induced by canatoxin, a convulsant protein: evidence for the involvement of the platelet lipoxygenase pathway.

C R Carlini, J A Guimarães, J M Ribeiro
PMCID: PMC1987286  PMID: 3919794

Abstract

Canatoxin is a toxic protein isolated from Canavalia ensiformis seeds. It induces death preceded by convulsions of spinal cord origin and also produces in vitro aggregation of platelets in rabbit, human and guinea-pig plasma. The aggregating effect is dose-dependent at nanomolar concentrations. Rabbit platelets pretreated with canatoxin became refractory to a second exposure to this protein or to collagen, but were still responsive to ADP, Paf-acether or arachidonic acid. [14C]-5-hydroxytryptamine was released from pre-labelled platelets on stimulation with canatoxin. Washed rabbit platelets, but not thrombin-degranulated ones, aggregated on stimulation with canatoxin provided that fibrinogen was added before the toxin. Canatoxin's pro-aggregating activity was inhibited by mepacrine, EDTA, caffeine, prostacyclin, adenosine monophosphate and also by the ADP scavenger system, creatine phosphokinase/creatine phosphate. Furthermore, 3-amino-1-[m-(trifluoromethyl)-phenyl]-2-pyrazoline (BW 755C), eicosatetraynoic acid (ETYA) and nordihydroguaiaretic acid (NDGA) were potent inhibitors of canatoxin-induced aggregation. In contrast, no inhibition was seen with indomethacin. The data indicate that canatoxin is mainly a release-reaction-promoting agent, being devoid of any direct aggregating activity. Thus the aggregation is totally dependent on the release of ADP. Furthermore, canatoxin-induced platelet activation is probably dependent on platelet phospholipase A2 and lipoxygenase activity but is not dependent on cyclo-oxygenase products or the release of Paf-acether.

Full text

PDF
551

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aharony D., Smith J. B., Silver M. J. Regulation of arachidonate-induced platelet aggregation by the lipoxygenase product, 12-hydroperoxyeicosatetraenoic acid. Biochim Biophys Acta. 1982 Oct 8;718(2):193–200. doi: 10.1016/0304-4165(82)90219-7. [DOI] [PubMed] [Google Scholar]
  2. Ardlie N. G., Packham M. A., Mustard J. F. Adenosine diphosphate-induced platelet aggregation in suspensions of washed rabbit platelets. Br J Haematol. 1970 Jul;19(1):7–17. doi: 10.1111/j.1365-2141.1970.tb01596.x. [DOI] [PubMed] [Google Scholar]
  3. BORN G. V., CROSS M. J. THE AGGREGATION OF BLOOD PLATELETS. J Physiol. 1963 Aug;168:178–195. doi: 10.1113/jphysiol.1963.sp007185. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Bills T. K., Smith J. B., Silver M. J. Metabolism of [14C]arachidonic acid by human platelets. Biochim Biophys Acta. 1976 Feb 23;424(2):303–314. doi: 10.1016/0005-2760(76)90198-3. [DOI] [PubMed] [Google Scholar]
  5. Blackwell G. J., Flower R. J., Nijkamp F. P., Vane J. R. Phospholipase A2 activity of guinea-pig isolated perfused lungs: stimulation, and inhibition by anti-inflammatory steroids. Br J Pharmacol. 1978 Jan;62(1):79–89. doi: 10.1111/j.1476-5381.1978.tb07009.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Boullin D. J., Glenton P. A. Characterization of receptors mediating 5-hydroxytryptamine- and catecholamine-induced platelet aggregation, assessed by the actions of alpha- and beta-blockers, butyrophenones, 5-HT antagonists and chlorpromazine. Br J Pharmacol. 1978 Apr;62(4):537–542. doi: 10.1111/j.1476-5381.1978.tb07758.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Brodde O. E., Eymer T., Arroyo J. 3H-yohimbine binding to guinea-pig kidney and calf cerebral cortex membranes: comparison with human platelets. Arch Int Pharmacodyn Ther. 1983 Dec;266(2):208–220. [PubMed] [Google Scholar]
  8. Carlini C. R., Gomes C., Guimarães J. A., Markus R. P., Sato H., Trolin G. Central nervous effects of the convulsant protein canatoxin. Acta Pharmacol Toxicol (Copenh) 1984 Mar;54(3):161–166. doi: 10.1111/j.1600-0773.1984.tb01912.x. [DOI] [PubMed] [Google Scholar]
  9. Carlini C. R., Guimarães J. A. Isolation and characterization of a toxic protein from Canavalia ensiformis (jack bean) seeds, distinct from concanavalin A. Toxicon. 1981;19(5):667–675. doi: 10.1016/0041-0101(81)90104-5. [DOI] [PubMed] [Google Scholar]
  10. Cazenave J. P., Benveniste J., Mustard J. F. Aggregation of rabbit platelets by platelet-activating factor is independent of the release reaction and the arachidonate pathway and inhibited by membrane-active drugs. Lab Invest. 1979 Sep;41(3):275–285. [PubMed] [Google Scholar]
  11. Cerletti C., Livio M., Doni M. G., De Gaetano G. Salicylate fails to prevent the inhibitory effect of 5,8,11,14-eicosatetraynoic acid on human platelet cyclo-oxygenase and lipoxygenase activities. Biochim Biophys Acta. 1983 Aug 23;759(1-2):125–127. doi: 10.1016/0304-4165(83)90197-6. [DOI] [PubMed] [Google Scholar]
  12. Costa J. L., Murphy D. L. Platelet 5-HT uptake and release stopped rapidly by formaldehyde. Nature. 1975 May 29;255(5507):407–408. doi: 10.1038/255407a0. [DOI] [PubMed] [Google Scholar]
  13. Croset M., Lagarde M. Stereospecific inhibition of PGH2-induced platelet aggregation by lipoxygenase products of icosaenoic acids. Biochem Biophys Res Commun. 1983 May 16;112(3):878–883. doi: 10.1016/0006-291x(83)91699-6. [DOI] [PubMed] [Google Scholar]
  14. Dutilh C. E., Haddeman E., Don J. A., ten Hoor F. The role of arachidonate lipoxygenase and fatty acids during irreversible blood platelet aggregation in vitro. Prostaglandins Med. 1981 Feb;6(2):111–126. doi: 10.1016/0161-4630(81)90081-1. [DOI] [PubMed] [Google Scholar]
  15. Dutilh C. E., Haddeman E., ten Hoor F. Role of the arachidonate lipoxygenase pathway in blood platelet aggregation. Adv Prostaglandin Thromboxane Res. 1980;6:101–105. [PubMed] [Google Scholar]
  16. Gorman R. R., Bunting S., Miller O. V. Modulation of human platelet adenylate cyclase by prostacyclin (PGX). Prostaglandins. 1977 Mar;13(3):377–388. doi: 10.1016/0090-6980(77)90018-1. [DOI] [PubMed] [Google Scholar]
  17. Graf M., Pletscher A. Shape change of blood platelets--a model for cerebral 5-hydroxytryptamine receptors? Br J Pharmacol. 1979 Apr;65(4):601–608. doi: 10.1111/j.1476-5381.1979.tb07870.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Hamberg M. On the formation of thromboxane B2 and 12l-hydroxy-5,8,10,14-eicosatetraenoic acid (12 ho-20:4) in tissues from the guinea pig. Biochim Biophys Acta. 1976 Jun 22;431(3):651–654. doi: 10.1016/0005-2760(76)90232-0. [DOI] [PubMed] [Google Scholar]
  19. Hamberg M., Samuelsson B. Prostaglandin endoperoxides. Novel transformations of arachidonic acid in human platelets. Proc Natl Acad Sci U S A. 1974 Sep;71(9):3400–3404. doi: 10.1073/pnas.71.9.3400. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Higgs G. A., Flower R. J., Vane J. R. A new approach to anti-inflammatory drugs. Biochem Pharmacol. 1979 Jun 15;28(12):1959–1961. doi: 10.1016/0006-2952(79)90651-8. [DOI] [PubMed] [Google Scholar]
  21. Higgs G. A., Vane J. R. Inhibition of cyclo-oxygenase and lipoxygenase. Br Med Bull. 1983 Jul;39(3):265–270. doi: 10.1093/oxfordjournals.bmb.a071831. [DOI] [PubMed] [Google Scholar]
  22. Jenkins C. S., Packham M. A., Kinlough-Rathbone R. L., Mustard J. F. Interactions of polylysine with platelets. Blood. 1971 Apr;37(4):395–412. [PubMed] [Google Scholar]
  23. Kattlove H. E., Gomez M. H. Studies on the mechanism of ristocetin-induced platelet aggregation. Blood. 1975 Jan;45(1):91–96. [PubMed] [Google Scholar]
  24. Kinlough-Rathbone R. L., Chahil A., Packham M. A., Reimers H. J., Mustard J. F. Effect of ionophore A23, 187 on thrombin-degranulated washed rabbit platelets. Thromb Res. 1975 Sep;7(3):435–449. doi: 10.1016/0049-3848(75)90038-9. [DOI] [PubMed] [Google Scholar]
  25. Kinlough-Rathbone R. L., Mustard J. F., Perry D. W., Dejana E., Cazenave J. P., Packham M. A., Harfenist E. J. Factors influencing the deaggregation of human and rabbit platelets. Thromb Haemost. 1983 Jun 28;49(3):162–167. [PubMed] [Google Scholar]
  26. Kirby E. P., Mills D. C. The interaction of bovine factor VIII with human platelets. J Clin Invest. 1975 Aug;56(2):491–502. doi: 10.1172/JCI108116. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Lapetina E. G., Chandrabose K. A., Cuatrecasas P. Ionophore A-23187- and thrombin-induced platelet aggregation: independence from cycloxygenase products. Proc Natl Acad Sci U S A. 1978 Feb;75(2):818–822. doi: 10.1073/pnas.75.2.818. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Mustard J. F., Packham M. A. Factors influencing platelet function: adhesion, release, and aggregation. Pharmacol Rev. 1970 Jun;22(2):97–187. [PubMed] [Google Scholar]
  29. Mustard J. F., Packham M. A., Kinlough-Rathbone R. L., Perry D. W., Regoeczi E. Fibrinogen and ADP-induced platelet aggregation. Blood. 1978 Aug;52(2):453–466. [PubMed] [Google Scholar]
  30. Nishizawa E. E., Williams D. J., Connell C. L. Arachidonate induced aggregation of rat platelets may not require prostaglandin endoperoxides or thromboxane A2. Thromb Res. 1983 May 1;30(3):289–296. doi: 10.1016/0049-3848(83)90082-8. [DOI] [PubMed] [Google Scholar]
  31. Prado-Franceschi J., Tavares D. Q., Hertel R., Lobo de Araújo A. Effects of convulxin, a toxin from rattlesnake venom, on platelets and leukocytes of anesthetized rabbits. Toxicon. 1981;19(5):661–666. doi: 10.1016/0041-0101(81)90103-3. [DOI] [PubMed] [Google Scholar]
  32. Sneddon J. M. Blood platelets as a model for monoamine-containing neurones. Prog Neurobiol. 1973;1(2):151–198. doi: 10.1016/0301-0082(73)90019-1. [DOI] [PubMed] [Google Scholar]
  33. Taylor G. W., Morris H. R. Lipoxygenase pathways. Br Med Bull. 1983 Jul;39(3):219–222. doi: 10.1093/oxfordjournals.bmb.a071822. [DOI] [PubMed] [Google Scholar]
  34. Vargaftig B. B., Chignard M., Benveniste J. Present concepts on the mechanisms of platelet aggregation. Biochem Pharmacol. 1981 Feb 15;30(4):263–271. doi: 10.1016/0006-2952(81)90052-6. [DOI] [PubMed] [Google Scholar]
  35. Vargaftig B. B., Chignard M., Le Couedic J. P., Benveniste J. One, two, three or more pathways for platelet aggregation. Acta Med Scand Suppl. 1980;642:23–29. doi: 10.1111/j.0954-6820.1980.tb10931.x. [DOI] [PubMed] [Google Scholar]
  36. Vargaftig B. B., Hai N. D. Selective inhibition by mepacrine of the release of "rabbit aorta contracting substance" evoked by the administration of bradykinin. J Pharm Pharmacol. 1972 Feb;24(2):159–161. doi: 10.1111/j.2042-7158.1972.tb08953.x. [DOI] [PubMed] [Google Scholar]
  37. Vargaftig B. B., Joseph D., Wal F., Marlas G., Chignard M., Chevance L. G. Convulxin-induced activation of intact and of thrombin-degranulated rabbit platelets: specific crossed desensitisation with collagen. Eur J Pharmacol. 1983 Aug 19;92(1-2):57–68. doi: 10.1016/0014-2999(83)90108-5. [DOI] [PubMed] [Google Scholar]
  38. Vargaftig B. B., Prado-Franceschi J., Chignard M., Lefort J., Marlas G. Activation of guinea-pig platelets induced by convulxin, a substance extracted from the venom of Crotalus durissus cascavella. Eur J Pharmacol. 1980 Dec 19;68(4):451–464. doi: 10.1016/0014-2999(80)90420-3. [DOI] [PubMed] [Google Scholar]
  39. Vargaftig B. B., Zirinis P. Platelet aggregation induced by arachidonic acid is accompanied by release of potential inflammatory mediators distinct from PGE2 and PGF2. Nat New Biol. 1973 Jul 25;244(134):114–116. doi: 10.1038/newbio244114a0. [DOI] [PubMed] [Google Scholar]
  40. Watanabe T., Narumiya S., Shimizu T., Hayaishi O. Characterization of the biosynthetic pathway of prostaglandin D2 in human platelet-rich plasma. J Biol Chem. 1982 Dec 25;257(24):14847–14853. [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES